




\* ) + ( , " , - . / 0 1 ) \$ 2 " 3 ) #

4+#)



!"#\$

!"#\$

%&'(#)\*#+, -. !

%/#01! -2"#. . #3,

45#6789: ;: <


=5;8>#?@5>: <;: A5>#(#\*BC#. . 5>D

3ED#?@5>: <;: A5>#(##OB)#. . 5>D

=F#(##OBG#. . 5>D

H@8;

!"#\$



!"#\$%&'()\*+,-./:;<=>@A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

%&'(#)2#+, -. !  
%/#01!-2"#. . #3,  
45#6789: ;: <

=5;8>#@5> <; A5>#(#\*BC#. . 5>D  
3ED#@5> <; A5>#(##OB)#. . 5>D  
=F#(##OBG#. . 5>D

H@8; <#@: A#A7<+I

00#K;< (#GM#A7<+#5N#OP#: Q: R;#R#0"#S: 8A<  
T>5U#A7<+V





56+2.+().7).8"##", -9.



Honigsberg M et al JACC 2020

56+2.+().7).8"##", -9.



56+2.:)%#);.+().7).8"##", -9.

\*"#+

- ?@"A/\*+'"\$<2-"D+&\$+"D+;/;/><\*, D'&\*
- : F#"G"CH"B9I, !
- : ("JK?IH@", , "49
- 3\$"2&\*L/=/'
- M\$=\*<">)\$</' =/+<"G"N0P", , \$<IQ
-

\*"#+

- ?@A/\*+' "\$<2-"D+&\$+"D+;/;/><\*, D' &\*
- : F#"G"CH"B9I, !
- : ("JK?IH@", , "49
- 3\$"2&\*L/=/'
- M\$=\*<">)\$</' =/+<"G"N0P", , \$<IQ
- 4RQ">)\$</' =/+<"G""J0C", , \$<IQ
- MS"G"J0T"
- QRQ;1"G"P0?
- 8D\$: G"J0K-"QDU\*V"G"T?", 9I2Q

!%&'() %\*+,+ -\*. '/0+'1"2)'!"3-+'. -'4"#5

- 8"<\*+9/"D+\$D\$+=&\$%) \*0/"<\$E"" )\$+=;= /+, " : WM")&9)"  
&7/=&, /"+&' B-"LX="E) \*=">\*%"E/"2\$Y

!"#\$%&'( )&\*)+,&-. +/01#\$


203\$-#4&\$\*+/%&)+'053-+0\$+

20\$-&"# ,+

6, #7#\$%8%&7#+% , #8%1 # \$%9

$\langle +(\%_{\theta} \cdot) () 3), 2+2^{\#}3).2() +28), 29$


<?@\*A.6=>) (2) , #"& , .2()+28) , 29



Honigsberg M et al Circulation 2020




<?\*A.\$6&%)#2) (&%2()+28), 29





\*"B) C%&, -




22M#A<+A: 6W?;75R#7R#03E

46%) #2) (&%D() +28) , 2.D(" +%"#2#

5-year MVE    Events (% per annum)    RR (CI) per 1.0 mmol/L reduction    Trend test



<+ (%) (. "#.0) 22) (




XR76: A. 8R : ;#8>#Z & ZL08A675>5, S#) "OG

+>&%>&>(&2)" , .E




?>&E

Figure 1. Apolipoprotein B48 and B100 Lipoprotein Particles




F<sup>+</sup>-6.+>&E G.H+, -)(





@ "# | . 2 ( + \$ | # . ? > & E C + % 7 + = #




\*" > & > (&2) " , : + ; 9


56+2."#.\*>:+;9

- ApoB+apo(a) Lp(a)
- Lp(a) levels are almost entirely mediated by genetics
- Highly atherogenic, pro-calcific
- Most common genetic dyslipidemia  
(


56+2."#.\*>:+;9



\*>: + ; . "# . + 26) (& - ) , "\$








## Treatment approaches for raised Lp(a)

1. Control diabetes and other risk factors

2. Controlling dyslipidemia with a statin to achieve a desirable non-HDL cholesterol level of <100 mg/dl (2.5 mmol/l)

3. Consideration of lipoprotein apheresis



37, @#DKT8V-37, @#DEDLO

D5U#DKT8V-37, @#DEDLO

37, @#DKT8V->5U#DEDLO

D5U#DKT8V->5U#DEDLO



\*"#+

- ?@A/\*+' "\$<2-"D+&\$+"D+;/;/><\*, D' &\*
- : F#"G"CH"B9I, !
- : ("JK?IH@", , "49
- 3\$"2&\*L/=/'
- M\$=\*<">)\$</' =/+<"G"N0P", , \$<IQ
- 4RQ">)\$</' =/+<"G""J0C", , \$<IQ
- MS"G"J0T"
- QRQ;1"G"P0?
- 8D\$: G"J0K-"QDU\*V"G"T?", 9I2Q

56+2J#.6) (.@<?\* ("#19..  
56+2J#.26).@<?\* 0), )B"29

- TZ"+&' B"\*="J@;A/\*+"UD+\$L\*L<A"3(4V
- 8=\$+0\*' =\*=&%"P@", 9"; ["QRQ;1"7+\$, "P0?"="\$C0T", , \$<IQ
- 855"G"J?Z"\ "U@0NNV"#\$ G"TZ"
- 33M"G"JI855"G"E/"%//2"=\$"=+/\*="JP"D\*=&/%="'\$0/+"  
J@"A/\*+' "\$D+/0/%="J"/0/%=
- ] ) \*="\*L\$X="7\$+"K@"A/\*+' Y""

# F&7.8' \$6.0), )B"29



Research

GENERAL

HEALTH

PHYSICS

CHEMISTRY

ENVIRONMENT

ENERGY

SPACE

...and term Benefit Approach to Standard Risk-Based ... AI

...in Disease Detection ... Approach for State ...

George Thanassoulis, MD, MSc, FRCPC, Allan D. Spiderman, MD, Michael J. Penciner, PhD

## CONCLUSIONS AND RELEVANCE A long-term benefit approach to statin eligibility identifies

...and term Benefit Approach to Standard Risk-Based ... AI

...in Disease Detection ... Approach for State ...

# K' 88+(=

- $1^{\wedge} + \&' B \&\% " E \$ , / \% " \&' " 7 + / \_ X / \% = \langle A " X \% 2 / + / ' = \& , * = / 2$   
:  $\& * ) + 4 \&' \# \% \& 1 \# + , \& - . + " \# - 6 \&\% \# + \$ 0 \% + \# 4 \& * \& ; 4 \# + ' 0 , + \% 8 \% \& \$ -$
- $3 // 2 " = \$ " L / = = / + " * ' ' / ' ' " * \langle \langle " \$ X + \rangle / ' " \$ 7 " 1^{\wedge} + \&' B$   
:  $( 6 \# , \% \# \$ - \& 0 \$ + " \& - 0 , " \# , - + 0 ' + 6 , \# * \$ 8 \$ 5 ($   
 $\langle \& 6 0 6 , 0 \% \# \& \$ -$
- $\` , D ) * ' \&a / " \& 7 / ' = A \langle / " \rangle ) * \% 9 / " \&\% " / * + \langle A " \& 7 / " L X = " \rangle \$ \% ' \& 2 / + "$   
 $D + / 0 / \% = * = \& 0 / " = ) / + * D A " E ) / \% " D \$ = / \% = \& * \langle " L / \% / 7 \& = " \&' " \rangle \& 9 )$   
 $\# 7 \# \$ + \&' + \# - \% \& 1 8 \% \# " + , \& - . + \& - + = 4 0 / >$